# LadRx Corp > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/LadRx Corp). ## Overview LadRx Corp is a Delaware-based biopharmaceutical research company focused on oncology drug discovery and clinical development. Its core platform, LADR™, is designed to target chemotherapeutic drugs to solid tumors while reducing off-target toxicities, and the company also developed a companion diagnostic, ACDx™, to identify patients most likely to benefit from treatment. ## Products & services • LADR™ targeted oncology drug candidates • LADR-7, LADR-8, LADR-9 and LADR-10 programs • ACDx™ companion diagnostic • Royalty and licensing rights tied to arimoclomol and ImmunityBio agreements • Advisory, consulting, financial and administrative services to Centurion (historical) - **LADR™ oncology therapeutics** (0%) — Targeted anti-cancer drug candidates designed to deliver chemotherapeutic payloads to solid tumors and reduce toxicity. - **Companion diagnostics** (0%) — ACDx™ diagnostic tools intended to identify patients most likely to respond to the company’s drug candidates. - **Licensing, royalties and milestones** (100%) — Contractual rights to receive milestone, royalty and related payments from partnered assets and license agreements. - **Corporate and administrative services** (0%) — Historical management, consulting and administrative support provided to the Centurion subsidiary structure. - LADR™ targeted anti-cancer drug platform - LADR-7 through LADR-10 preclinical oncology candidates - ACDx™ companion diagnostic for patient selection - Royalty and milestone rights from licensing agreements - Management and administrative services to Centurion (historical) ## Customers LadRx does not currently operate as a commercial drug seller; its economic counterparties are primarily pharmaceutical partners, licensees, and potential strategic collaborators. In practice, value is created for oncology drug developers, clinical-stage partners, and acquirers that may license or fund the LADR platform and related assets. The company also depends on capital providers and transaction counterparties to monetize its intellectual property while it remains pre-revenue. - **Pharmaceutical licensing partners** (primary) — Companies that license LADR-based assets or related rights to advance oncology programs and commercialize them. - **Strategic development partners** (primary) — Biopharma collaborators that may fund trials, share development risk, or enter joint ventures around the platform. - **Royalty and milestone counterparties** (secondary) — Partners obligated to pay contingent consideration under prior license or assignment agreements. - **Capital providers** (primary) — Equity investors, lenders, or other financing sources needed to sustain operations and development work. - Pharma partners seeking licensed oncology assets - Potential strategic collaborators funding development - Licensees paying milestones, royalties or upfront fees - Investors and financing counterparties supporting operations - Regulatory and clinical stakeholders enabling development ## Geography LadRx is headquartered in Los Angeles, California, and is incorporated in Delaware. Its historical research footprint included a discovery laboratory in Freiburg, Germany, but that lab was closed in 2019, so current operations are largely U.S.-based with international exposure mainly through intellectual property and licensing arrangements. - Head office in Los Angeles, California - Incorporated in Delaware - Historical discovery lab in Freiburg, Germany - International exposure through patents and licensing rights - No disclosed country revenue mix; company has no recurring revenue ## Strategy The company’s strategy is to preserve and monetize the LADR platform through strategic partnerships, licensing, royalty sales, grants, or equity financing. Near term, management is focused on securing capital and/or a transaction that can fund continued development, because the business currently has no recurring revenue and remains a going-concern risk. - **Secure financing or strategic partnership** (short-term) — The company has no recurring revenue and needs external capital to continue operating. - **Monetize LADR intellectual property** (medium-term) — Licensing and partnering are the main paths to value creation for a pre-commercial biotech. - **Advance lead oncology candidates** (medium-term) — Clinical progress is needed to improve partnering leverage and long-term asset value. - Monetize LADR technology through partnerships or licensing - Seek non-dilutive or strategic financing to fund operations - Advance lead oncology candidates toward clinical entry - Use intellectual property to create optionality for transactions - Reduce cash burn while preserving platform value ## Risks LadRx is a pre-revenue biotech with substantial going-concern risk, so its survival depends on successful financing or partnering. Its value is also highly dependent on clinical, regulatory, and intellectual property outcomes, while royalty and milestone monetization can be volatile and non-recurring. - **Going-concern uncertainty** [critical] — The company has no recurring revenue and expects continued losses unless it secures financing or a strategic partnership. - **Clinical development failure** [high] — LADR candidates are still dependent on preclinical and future clinical success, which is uncertain in oncology. - **Regulatory approval risk** [high] — Drug candidates and any derived products require FDA and other regulatory approvals before commercialization. - **Intellectual property risk** [high] — The business depends on patent protection and enforceability of its LADR technology and related rights. - **Counterparty and monetization risk** [medium] — Royalty and milestone receipts depend on partner performance and contractual triggers, which may not occur. - Going-concern risk if financing or partnerships do not materialize - No recurring revenue and limited operating cash generation - Clinical and regulatory failure risk for oncology candidates - IP and patent protection risk for the LADR platform - Dependence on counterparties for milestone and royalty payments ## Accounting The most important accounting issues are the treatment of royalty monetization, stock-based compensation, and impairment/valuation judgments. Management also highlights estimates around revenue recognition, long-lived assets, R&D and clinical trial costs, while the company’s non-recurring income makes period-to-period comparability difficult. - **Royalty monetization accounting** — Affects reported revenue, other income, and operating performance comparability - **Stock-based compensation** — Impacts operating loss and non-cash expense trends - **Impairment of long-lived assets and intangibles** — Could trigger write-downs and reduce asset values - **R&D and clinical trial accrual estimates** — Affects quarterly expense recognition and liabilities - **Going-concern disclosure** — Signals liquidity risk and affects valuation assumptions - Royalty agreement accounted for as ASC 610-20, not revenue - Stock-based compensation valued with Black-Scholes assumptions - Impairment judgments for long-lived and intangible assets - Estimates for R&D and clinical trial expense accruals - Non-recurring milestone income distorts quarterly comparability --- *Last updated: 2026-04-28T20:22:07.144677+00:00*